In last years, following the increased canine life expectancy and the rising attention pet-owners devote to their animals, several authors have carried on investigations concerning new techniques to early identify canine prostatic disorders that might affect the dog's quality of life. Prostatic disorders often have an asymptomatic onset and their early diagnosis is difficult: hence, they are usually identified at an advanced stage, only. Traditionally, the diagnosis of prostatic disorders is based on noninvasive tools, such as transrectal and abdominal palpation, seminal or prostatic fluid evaluation, and urinalysis and imaging. On the other hand, a definite diagnosis of prostatic abnormalities could be achieved through prostatic parenchyma Fine Needle Aspiration (FNA) or biopsy. However, these investigations are performed rarely because of their invasiveness. Thus, several authors investigated canine serum biomarkers in order to achieve an earlier diagnostic timing and to apply therapeutic strategies for better outcomes. The Canine Prostatic Specific Esterase (CPSE) has been identified as a suitable biomarker to be included in a prostate health screening program, following the model of prostatespecific antigen (PSA) in human medicine. A higher CPSE in dogs suffering from several prostatic diseases, such as benign prostatic hyperplasia, bacterial prostatitis, or prostatic carcinoma, was reported in literature. Thanks to the potential usefulness in clinical practice, further studies should investigate the potential role of CPSE in monitoring the medical treatment success in the male reproductive system. Moreover, the spreading availability of serum biomarkers, easily carried out on blood samples in clinical practice, could assure a more accurate evaluation of the actual prevalence of prostatic disorders. The CPSE is actually recognized as a promising diagnostic tool for the detection of prostatic disorders in a "prostate health screening program," in order to properly select those patients requiring further more accurate and expensive diagnostic investigations.
Introduction
Recently, several authors have carried on research activities concerning new techniques to early identify canine prostatic disorders that might also affect life quality. Such improvements have been allowed from the increased attention pet-owners devote to their animals, the increased canine life expectancy, the improved veterinary care, and the most recent diagnostic possibilities. [1] [2] [3] [4] The most important diseases of the gland include benign prostatic hyperplasia (BPH), prostatic cyst, prostatitis, and prostatic neoplasia. 5 Canine prostatic disorders remain subclinical at their onset, thus it is difficult to diagnose them in early stages and they are mostly recognized at an advanced stage, only. 2, 6 In clinical practice, the delayed diagnosis usually follows late clinical signs reported in combination with an enlarged gland though dogs might have an enlarged prostate in absence of symptoms. 7 When defining the stage of the disease at diagnosis, the dog's lifestyle plays an important role: in pet-dogs, prostatic disorders are often unnoticed at their beginning because they are asymptomatic or show only very mild clinical signs, such as the detection of blood drops in urine. 6, 8 In stud dogs, these disorders are diagnosed more frequently as they are presented for poor fertility 9 or they undergo deeper male breeding soundness examinations after decreased libido or detection of blood in the prostatic fluid of the ejaculate. 6, 8 In human medicine, diagnostic tools for the investigation of prostatic disorders recorded a great improvement, mainly through the serum dosage of the prostate-specific antigen (PSA). As a result, the incidence of diagnosed prostatic diseases increased, thanks to the possibility of identifying subclinical asymptomatic cases 4 . The PSA is a proteolytic glycoprotein present in normal prostatic tissue in men while it increases with BPH, prostatitis, and malignant neoplasia. [10] [11] [12] [13] [14] [15] For the above mentioned reasons, several researchers began to look for canine serum biomarkers similar to those routinely used in human andrology, in order to achieve a similar diagnostic timing and to apply earlier therapeutic strategies for better outcomes. [16] [17] [18] [19] A more accurate evaluation of the prevalence of prostatic disorders could be achieved with a prostate health screening program, easily performed on blood samples thanks to the availability of serum biomarkers. 1 The 3 most important markers in the canine male genital tract are represented by alkaline phosphatase, carnitine, and Canine Prostatic Specific Esterase (CPSE). 20 Alkaline phosphatase and carnitine are linked to epididymis and ductal network disorders. 20 Serum prostatic acid phosphatase and PSA are successfully used to diagnose prostatic carcinoma in men, while these markers are still controversial in dogs because acid phosphatase resulted nonspecific and PSA does not seem to increase in canine prostatic neoplasia, 21, 22 the latter being excluded from canine clinical practice. 23 Recently, some literature studies reported a higher CPSE in dogs suffering from several prostatic diseases: BPH, bacterial prostatitis, or prostatic carcinoma. 3, 18, [24] [25] [26] Since then, serum arginine esterase has routinely been used in the diagnosis of prostatic hyperplasia, 19, 27 though its role in different prostatic alterations has not yet been completely understood. 25, 28 The objective of the present review was to give a complete clinical description of the diagnostic value of CPSE, describing in detail several aspects of the composition and of the biological role of this enzyme, in order to highlight the diagnostic usefulness of this marker and its possible perspectives for future research and clinical applications.
Discovering Canine Prostatic Specific Esterase
The seminal fluid of all mammalian species contains various proteinases, thus the presence of proteolytic activity in canine seminal plasma was expected. 29 In humans, PSA, seminal plasma acidic protease, neutral protease, and plasminogen activator have deeply been investigated. [30] [31] [32] In dogs, instead, a markedly different arginine esterase activity was first described in 1956, when it was identified in great levels in canine prostatic fluids. 33 Since the '80s, CPSE, that is the major androgen-dependent secretory product of the canine prostatic gland, was suggested as a useful diagnostic biomarker to identify dogs suffering from prostatic diseases. 16, 22 Arginine esterase is one of the most abundant proteins in the canine seminal plasma, 34 accounting for more than 90% of seminal proteins in dogs, 16, 28 identified in similar quantities in all ejaculate fractions. 35 The CPSE is mainly present in the apical region of the canine prostatic secretory epithelial cells. 36 In polyacrylamide gel electrophoresis, CPSE has a molecular weight of 29 kDa. Under denaturant conditions, in the presence of mercaptoethanol and SDS gel, it undergoes the rupture of disulfide bridges linking its 2 constituting protein chains, originating 2 protein bands of 15 kDa and 14 kDa, respectively. 16 Different isoforms were identified by column chromatofocusing and 2-dimensional electrophoresis, based on their isoelectric points. 37, 38 Their heterogeneity is probably due to a different glycoside content. 36 The CPSE was also associated to the class of kallikreins 39 as its amino acid sequence has a 64% homology with swine pancreatic kallikrein and its molecular weight is similar to salivary glands kallikrein, though, contrary to them, it is not able to hydrolyze canine seminal plasma kininogen.
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The CPSE was compared to PSA: their enzymatic activity turned out not to be completely superimposable because CPSE is a trypsinlike enzyme and PSA has also a chymotrypsin-like effect. 42 Though being 2 clearly distinct molecules, 42 they have similar molecular weight (29 kDa for CPSE and 34 kDa for PSA); they are both enzymes of the serine-proteases class and have a 58% homology in the 30th-NH2 terminal portion of the amino acid sequence. 42 Recently, a strong taxonomic and genomic correlation between PSA and CPSE was found, making the dog a very suitable model for further studies and comprehension of human prostatic disorders. 43 In men, the function of PSA is to hydrolyze the clot formed by seminal substances just after their emission; canine ejaculate does not form any clot, thus the CPSE activity turns out to be not clear though its role in the melting of the female genital tract mucus can be assumed. 44 Seminal plasma proteins can exert diverse effects on sperm functions 45, 46 ; among them, CPSE is a multifunctional protein thanks to its zinc-binding properties. 38 The enzyme was first detected in the postacrosomal region and in the sperm tail of ejaculated spermatozoa, but it was not found in epididymis spermatozoa. 35 The CPSE plays a relevant role in the binding of phosphorylcholine-binding proteins to choline phospholipids of the sperm plasma membrane; at ejaculation, this process induces a cholesterol efflux, an essential step for the capacitation process. 47 Thus, CPSE can be counted among sperm-binding proteins and is possibly implicated in sperm fertilization-related events. 38 The CPSE may also affect the tail of spermatozoa where it was identified by immunofluorescence. 40 Further studies are needed to clarify the specific role of CPSE in the egg-sperm fertilization process. 48 Along with prostatic pathologies, when the architecture of the gland is widely damaged, independently from its grounding cause, 49 CPSE is released by the prostate gland also in blood, where it can be dosed on serum samples. 25 At the very beginning, CPSE was dosed by a radioimmunoassay determination, 50 while today new techniques are available in ELISA immunoassay kits (Speed CPSE, Virbac BVT, France), which are fast, easy and ready to use afield in everyday clinical settings. Thus, CPSE has been identified as a suitable biomarker to be included in a prostate health screening program, following the model of PSA in human medicine.
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Using Canine Prostatic Specific Esterase in Canine Clinics
Traditionally, the diagnosis of prostatic disorders is based on noninvasive tools, such as the transrectal and abdominal palpation, the seminal or prostatic fluid evaluation, and urinalysis and imaging. On the other hand, a definite diagnosis of prostatic disorders could be reached by prostatic parenchyma Fine Needle Aspiration (FNA) or biopsy, but they are rarely performed due to their invasiveness. 23 Moreover, to identify any coexistence of BPH and prostatitis, a bacterial exam complete with antibiogram and a cytologic exam should be performed either on prostatic fluids or on fine-needle aspiration of the prostatic parenchyma or on urine, 51 even though a surely more invasive prostatic tissue culture could represent a more accurate technique for the diagnosis of a prostatic infection. 52, 53 Obviously, the clinical evaluation of a prostatic disease must include complete haemato-biochemical exams, with special attention to CPSE. In addition to the ultrasonographic exam, CPSE, marker for prostatic secretion, can widely be used to explore the canine prostate, though its exact role in the different prostatic disorders has not yet been completely understood. 25, 50 Higher serum CPSE concentrations were reported in dogs affected by BPH, bacterial prostatitis, and prostatic carcinoma than in normal dogs, but they did not differ significantly among specific pathologies. 22 Coexistence of prostatitis or neoplasia together with BPH may justify some overlapping in serum CPSE. 22 A different study reported a higher CPSE in BPH dogs than in dogs affected by bacterial prostatitis or prostatic carcinoma. 54 The CPSE was also dosed in urine samples: in healthy dogs, it ranged from 20 to 300 mg/mL, while it was possible to distinguish patients with acute (1000-2000 mg/mL) or necrotizing (5-10 mg/mL) prostatitis. 24 An ultrasonographic exam of the prostate is strongly recommended when a dog is presented for poor fertility 9 as well as when a presumptive diagnosis of BPH is based on the detection of blood in the prostatic fluid of the ejaculate or in case of a presumptive diagnosis of chronic prostatitis based on signs of infertility or decreased libido. 6, 8 A recent retrospective work, involving 1003 intact male dogs, assessed that over 40% of the expected life of the dog, calculated according to its breed, an ultrasonographic screening program would be advisable as it is highly probable that abnormal prostatic findings are detected with the sonographic exam, irrespectively of clinical evidence. 2 The ultrasonographic examination should evaluate an altered aspect of echotexture, abnormal borders as well as the presence of single or multiple cysts. 55 Several authors evaluated the echographic volume of the prostate as a possible indicator for BPH. On the other hand, the increased prostatic volume is not enough to surely diagnose BPH, because it is present also in case of prostatitis and neoplasia. 5 However, a clear threshold measure to identify the normal volume of the canine prostate does not exist. A tool that has been developed to make objective prostatic volume considerations is represented by the ratio between the actual volume of the prostate (V = H £ L £ W £ 0.523) 56 and the estimated normal one (V = 0.33 £ BW + 3.28). 57 Recent studies correlated the echographic findings of the prostate, focusing the attention on the actual and/or normal estimated volume ratio (V-ratio), and the serum CPSE, either symptomatic or asymptomatic. In 2017, the diagnostic potential of CPSE was exploited in a prospective research enrolling 79 intact male dogs. The authors of the study assessed that in symptomatic patients, a V-ratio 2.5 and a serum CPSE 90 mg/mL have to be expected. 19 In 2018, the role of CPSE in a wider concept of preventive screening for canine prostatic health was defined, establishing the CPSE threshold to early identify asymptomatic dogs already affected by ultrasonographically detectable signs of prostatic alterations that could require further clinical investigations. 1 Among the 19 patients enrolled in this prospective study-though they were all asymptomatic-60% showed ultrasonographic prostatic alterations. The concentration of CPSE was significantly associated with the presence of ultrasonographic prostatic abnormal findings. By a Receiver Operating Characteristics (ROC) curve (Area Under the Curve (AUC) = 0.974, Sensitivity (SE) 95.6%, and Specificity (SP) 89.2%), the cutoff CPSE threshold of 52.3 ng/mL was endorsed to early identify those asymptomatic dogs already having sonographic alterations and thus requiring further evaluations, before becoming clinically ill. In the study, normal dogs had a V-ratio < 1.5, while dogs requiring further evaluations resulted to have a V-ratio 1.5. Finally, it was recently proved that ejaculation induces a spread in the prostatic vascularization. 58, 59 Thus the increased blood flow turns a greater CPSE amount away from the gland, resulting in higher serum CPSE, as recently reported by the authors in the 2018 European Veterinary Society for Small Animal Reproduction (EVSSAR) Congress. 60 The higher basal CPSE is, the higher is the peak, they both being more pronounced in dogs with prostatic alterations. Twenty-four hours after ejaculation, serum CPSE achieves basal values again. However, the relationship between basal and postejaculation CPSE was the same in healthy dogs, in animals suspected for prostatic disorders as well as in dogs diagnosed with glandular diseases. These physiological effects of ejaculation should be taken into account whenever CPSE dosage is planned to preventively select patients needing further prostatic evaluations. A 24 hours' proper sexual rest is recommended before the examination to exploit this diagnostic tool at best. 60 
Canine Prostatic Specific Esterase Perspectives
The CPSE prostatic screening suggested for clinical practice aims at identifying subclinical under-diagnosed prostatic diseases, affecting male fertility, life quality, and canine breeding performances. A noninvasive screening of the prostatic health would be advisable as part of the routine preventive medicine program in dogs. The early detection of the most common prostatic disorders would allow the clinician to suggest specific follow-up and to recommend efficient therapeutic protocols. 2 Thus, because of the potential usefulness of this tool in clinical practice, further studies should investigate the suitable role of CPSE in monitoring the medical treatment success in male reproductive system. The secretion of CPSE is regulated by androgen hormones, mainly represented by testosterone: thus, it could be inhibited by surgical or medical castration or by antiandrogen treatments. 16, 51, [61] [62] [63] On the contrary, CPSE synthesis could be promoted by an exogenous androgen administration following surgical castration. 61, 62 Finally, it has recently been demonstrated that in dogs with subclinical BPH, serum CPSE dosages significantly decrease under osaterone treatment. 27 The debate on the management and therapy of canine prostatic abnormalities is still in progress, 3, 5, [64] [65] [66] but the current availability of medical treatments prompts the development of a screening program, aiming at avoiding potentially more invasive options, that is surgical orchiectomy, to prevent the adverse effects of surgical castration 67 and/or to preserve the reproductive career of a stud.
Conclusions
Evidently, though having a different biological activity (CPSE: trypsin-like; PSA: chymotrypsin-like), the canine CPSE and the human PSA follow the same hormonal regulation. 41, 42 This is the reason why CPSE is recognized as a promising diagnostic tool for the detection of prostatic disorders in a "prostate health screening program," as it is the case for PSA in human medicine. 25 In Table 1 , clinical applications of blood serum CPSE are summarized. In clinical practice, CPSE can be used as a diagnostic tool for BPH-related prostatic disorders to recognize affected dogs, with a cutoff of CPSE > 90 ng/mL, in the presence of clinical symptoms and a V-ratio 2.5. 19 Moreover, CPSE has to be considered in planning preventive screening for BPH-related prostatic disorders to preventively select dogs that would require further evaluations, with a CPSE threshold of 50 ng/mL, in absence of symptoms but already showing ultrasonographic alterations and a V-ratio 1.5. 1 Finally, the serum CPSE would become a suitable biomarker to monitor the medical treatment of prostatic disorders thanks to its noninvasiveness, cheapness, rapidity, and practicality.
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Complementary exams: seminal or prostatic fluid evaluation, urinalysis and imaging, prostatic parenchima FNA or biopsy, bacterial exam complete with antibiogram 23, [51] [52] [53] .
